biospecimen banks

CPDR Patient Education Program

Industry-Sponsored Clinical Trials and Projects

The CRC maintains a comprehensive portfolio of both investigator-initiated and industrysponsored clinical trials that cover the entire patient's "life cycle." Some of the trials, though industry sponsored, were investigator-initiated trials for which a proposal was submitted by CPDR to obtain funding. There are two types of these studies:

  • One is when we approach the industry with a proposal and request funding under a collaborative type of agreement; the ownership and control remains with CPDR but costs are supported by the company. One example of this is the CPDR Prostate Cancer Quality of Life Study that has been ongoing since 2003 and has a current enrollment of more 1,600 men. This study is a unique asset to the program in that it looks at patient-reported outcomes; however, it is a very costly endeavor due to its labor intensiveness. The study includes administration of the EPIC questionnaire along with the SF-36v2® health questionnaire to men newly diagnosed with prostate cancer at baseline (before treatment), and at eight other time points subsequent to their treatment for three years. After submission of a proposal to GlaxoSmithKline, it was accepted by the company for funding on a year-to-year basis and has thus far received approval for three years of funding.

  • The other type of study is to take an idea to a company for another application or therapeutic target using that company's existing technology. This approach usually results in work being conducted under a traditional clinical trial agreement where CPDR conducts the study, is reimbursed for the time spent working on the trial, and the data are supplied to the company who uses their resources for analysis.

  • All trials and projects are carried out with full approval of the respective IRBs.

 

Current Clinical Trials

1. A Multicenter Clinical Study of the Sonablate®500 for the Treatment of Locally Recurrent Prostate Cancer With HIFU - Click Here for Information on the Trial

2. Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
Click Here for Information on the Trial

3. - A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer
Click Here for Information on the Trial

 

CURRENT EVENTS


August 21, 2014

ERG Monoclonal Antibody [9FY] Patent Issued To The Uniformed Services University Of The Health Sciences Center For Prostate Disease Research & Biocare Medical

Concord, CA – The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has been awarded a patent in the United States (Patent No: US 8,765,916 B2) and Europe for ERG monoclonal antibodies. The patent is pending in Australia, Canada and Japan. ERG mouse antibody 9FY is a rigorously characterized antibody for its specificity of the ERG protein detection among the closely related members of the ETS transcription factor family in biological specimens.

Read Full Article

 

August 6, 2014

Genomic Health Announces Positive Topline Results of Additional, Large Independent Validation Study of Oncotype DX® Prostate Cancer Test with Multiple Clinical Endpoints

Redwood City, CA – PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX® Genomic Prostate Score (GPS) predicts multiple clinical endpoints related to disease aggressiveness in men with low- and intermediate-risk prostate cancer. This study validated the Oncotype DX prostate cancer test as a ...

Read Full Article

 

WRNMMC UsToo! Newsletter

Read the AUGUST 2014 Newsletter